Full Press Release Details
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-related Macular Degeneration (Wet AMD) One-year primary endpoint data.
REGN
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-related Macular Degeneration (Wet AMD) One-year primary endpoint data
Key Takeaway: Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-related Macular Degeneration (Wet AMD) One-year primary endpoint data